Table 1 Trial and Baseline Patient Characteristics, and Interventions

ASA Dose (mg/d)

325 then 81

100

162

100

300

325

75-325

75-100

75-162

Trial

Sun et al. [16]

Gao et al. [15]

CASCADE [21]

CRYSSA [22]

Gasparovic [23]

CREDO [18]

CURE [19]

PLATO [17]

TRITON- TIMI 38 [11]

n = CABG/total patients

n = 100/100

n = 249/249

n = 113/113

n = 300/300

n = 224/224

n = 83/2116

n = 2072/12562

n = 1261 (1899)/18624

n = 346 (485)/13608

Trial Characteristics

 No. of Centres

1

1

2

1

1

99

428

862

707

 Enrolment period

Nov 2006 – Feb 2008

Dec 2007 – Dec 2008

May 2006 – Jul 2008

Dec 2006 – Oct 2009

Jun 2010 – Feb 2013

Jun 1999 – Apr 2001

Dec 1998 – Sep 2000

Oct 2006 – Jul 2008

Nov 2004 – Jan 2007

 Treatment/Follow Up Post Randomization

30 (all)/49 (median) d

3 months (all)

12 months (all)

12 months (all)

6 months (all)

12 months (all)

9 months (mean)

224 days [7.5 months] (median)

14.5 months (median)

 Median Time to CABG Post Randomization

n/r (index CABG instead of PCI)

25.5 days (IQR 12–70.5)

~20 days

100 days [50]

 Treatment/Follow Up Post CABG

30 (all)/49 (median) d

3 months (all)

12 months (all)

12 months (all)

12 months (all)

~12 months (all)

~8 months (mean)

~200 days [6.7 months] (median)

~11.2 months (median)

 Funding

Public/ Industry

Public

Public/Industry

n/r

n/r

Industry

Industry

Industry

Industry

Patients

n = 99

n = 224

n = 113

n = 300

n = 219

n = 83

n = 2072

n = 1261

n = 346

 Mean Age (years)

65

59

67

59

65

61

64

64

61

 % Male

90

83

89

74

75

74

70

79

77

 BMI

31

26

28

26

29

29

27

n/r (28^b)

 Diabetes

35 %

40 %

29 %

0 % (excl)

38 %

22 %

27 %

32 %

28 %

 Hypertension

70 %

59 %

50 %

46 %

96 %

75 %

61 %

68 %

64 %

 Smoker

59.6 % (current/ former)

55.8 % (history of)

13.2 %

n/r

36 %

33 % (within 1 year)

64.5 % (current /former)

31.2 %

n/r (38 %^b)

 COPD

n/r

n/r

8.1 %

 Dyslipidemia

76 %

38 %

88 %

56 %

96 %

71 %

n/r

54 %

n/r (56 %^b)

 Prev MI

39 %

47 %

n/r

36 %

n/r

37 %

36 %

20 %

n/r (18 %^b)

 Prev stroke/TIA

5.1 %

4.9 %

n/r

n/r

n/r

n/r

3.9 %

3.9 %/3.1 %

7.8 %

 Periph Vasc Dz

5.1 %

n/r

n/r

n/r

n/r

6.2 %

9.7 %

7.6 %

7.0 %

 Chronic Renal Disease

excl Cr >130 μM

n/r

n/r

excl Cr >177 μM

n/r

n/r

n/r

4.8 %

n/r (11 % CrCl < 60 mL/min^b)

 Mean LVEF

n/r

60 %

54 %

54 %

53 %

 CHF

0 % (excl)

20.3 %

n/r

n/r

7.3 %

4.1 %

10.7 %

 Severe LV dysfunction

38 %(Gr 3 LV)

0 % (excl)

n/r

n/r

n/r

n/r

Excluded

3.9 % (EF ≤ 30 %)

1 % (Gr 4 LV)

 Previous PCI

n/r

13 %

16 %

n/r

17 %

7.4 %

10 %

n/r

 Previous CABG

n/r

0 % (excl)

0 % (excl)

n/r

n/r

8.5 %

4.6 %

1.5 %

2.9 %

 3VD

54 %

n/r

77 %

n/r

 LM

24.2 %

n/r

48 %

n/r

 ST depression

54.2 %

 ST elevation

2.7 %

33.0 % (persistent)

 Abnormal ECG

95.2 %

 Diagnosis: UA

73.9 %

64.1 % (UA/NSTEMI)

 Diagnosis: MI

26.1 % (all NSTEMI)

35.9 % (STEMI)

 Abnormal  ECG/enzymes

97.7 %

CABG

 % Off-pump CABG

0 %

58.0 %

3.6 %

100 %

0 %

 % arterial conduits

100 %

100 %

100 %

100 %

93 %

 Grafts or ^adiseased vessels

4.0

3.1

3.5 ± 0.7

3.2 ± 0.6

n/r

1–2 (31 %)

^a1 (14.4 %)

3–4 (60 %)

^a2 (61.5 %)

≥5 (8 %)

^a3 (20.5 %)

 Median (IQR) days to CABG (all)

25.5 (12–70.5)

~20

100(36)

 CABG pre-d/c

49 %

57 %

4.3 %

 Median (IQR) days to CABG pre-d/c

13 (8–21) vs 12 (8–19)

 CABG post-d/c

51 %

43 %

95.7 %

 Median (IQR) days to CABG post d/c

67.5 (38–141) vs 73 (36–129)

 Days off study drug before CABG

17 (9–33)

≤2d (30.1 %) 3-5d (43.8 %) >5 (26.1 %)

≤2d (25.1 %) 3-5d (29.0 %) >5 (45.4 %)

 Restarted treatment post CABG

76.1 % (66 never discontinued + 1451 resumed/1928; 78 data unavailable)

66.4 %

61.8 % (214/346); additional 21/173 prasugrel and 16/173 clopidogrel patients resumed open label clopidogrel

 Days off study drug after CABG

10 (6–25)

<7d (35.9 %)

n/r

7–14(16.8 %)

>14d (10.0 %)